全文获取类型
收费全文 | 29708篇 |
免费 | 2004篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 570篇 |
妇产科学 | 1481篇 |
基础医学 | 1627篇 |
口腔科学 | 339篇 |
临床医学 | 13977篇 |
内科学 | 3138篇 |
皮肤病学 | 358篇 |
神经病学 | 1608篇 |
特种医学 | 609篇 |
外科学 | 2130篇 |
综合类 | 203篇 |
一般理论 | 18篇 |
预防医学 | 3832篇 |
眼科学 | 92篇 |
药学 | 697篇 |
2篇 | |
中国医学 | 94篇 |
肿瘤学 | 920篇 |
出版年
2024年 | 62篇 |
2023年 | 2087篇 |
2022年 | 2745篇 |
2021年 | 2477篇 |
2020年 | 2454篇 |
2019年 | 1399篇 |
2018年 | 1516篇 |
2017年 | 1632篇 |
2016年 | 1687篇 |
2015年 | 1028篇 |
2014年 | 2008篇 |
2013年 | 1798篇 |
2012年 | 1147篇 |
2011年 | 951篇 |
2010年 | 1238篇 |
2009年 | 1147篇 |
2008年 | 759篇 |
2007年 | 700篇 |
2006年 | 587篇 |
2005年 | 502篇 |
2004年 | 512篇 |
2003年 | 429篇 |
2002年 | 435篇 |
2001年 | 355篇 |
2000年 | 309篇 |
1999年 | 344篇 |
1998年 | 249篇 |
1997年 | 190篇 |
1996年 | 221篇 |
1995年 | 178篇 |
1994年 | 115篇 |
1993年 | 70篇 |
1992年 | 72篇 |
1991年 | 51篇 |
1990年 | 74篇 |
1989年 | 55篇 |
1988年 | 68篇 |
1987年 | 63篇 |
1986年 | 3篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
94.
95.
96.
According to conservative estimates, >230 million people are infected with schistosomiasis,which becomes one of the most common parasitic diseases. This study focuses on investigating in vivo and in vitro effects of mmu-miR-92a-2-5p in Schistosoma japonicum-induced liver fibrosis by targeting TLR2. Through bioinformatic analysis, the overexpression of TLR2 and the down-regulation of mmu-miR-92a-2-5p were revealed in the progression of S. japonicum-induced liver fibrosis. BALB/C mice were taken advantage to construct normal control and schistosomiasis liver fibrosis (SLF) model. The mice in model groups were transfected recombinant lentivirus (Lenti-mmu-miR-92a-2-5p or Lenti-NC) to alter the expression of mmu-miR-92a-2-5p in vivo. HE and Masson staining were employed to observe the pathological changes and collagenous fibrosis. QRT-PCR showed that mmu-miR-92a-2-5p was decreased while TLR2 was elevated in the infected groups. However, lenti-mmu-miR-92a-2-5p group could inhibit liver fibrosis. Then the effect of mmu-miR-92a-2-5p on S. japonicum-induced liver fibrosis including cell apoptosis rates, proliferation and proteins related to liver fibrosis was examined in NIH-3T3 mouse embryonic fibroblasts. Moreover, the association between mmu-miR-92a-2-5p and TLR2 was detected by dual-luciferase reporter gene assay and the expression of cytokines IL-4, IFN-γ and TNF-α in SLF model was detected by ELISA. Further, the knockout of TLR2 in C57BL/6J mice was used to confirm the association between mmu-miR-92a-2-5p and TLR2. Thus, these findings demonstrated that mmu-miR-92a-2-5p inhibited S. japonicum-induced liver fibrosis by targeting TLR2 in vitro and in vivo. 相似文献
97.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
98.
100.